{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:50:15Z","timestamp":1787064615981,"version":"build-2736575974"},"reference-count":97,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.bbadis.2021.166294","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T21:41:47Z","timestamp":1634852507000},"page":"166294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication"],"prefix":"10.1016","volume":"1868","author":[{"given":"Zheng Yao","family":"Low","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley Jia Wen","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil K.","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2021.166294_bb0010","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","article-title":"The proximal origin of SARS-CoV-2","volume":"26","author":"Andersen","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbadis.2021.166294_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00836","article-title":"Molecular insights into SARS COV-2 interaction with cardiovascular disease: role of RAAS and MAPK signaling","volume":"11","author":"Wehbe","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0020","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3390\/v12091058","article-title":"Drug repositioning: new approaches and future prospects for life-debilitating diseases and the COVID-19 pandemic outbreak","volume":"12","author":"Low","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.bbadis.2021.166294_bb0025","first-page":"202","article-title":"COVID-19: a review on the novel coronavirus disease evolution, transmission, detectionControl and Prevention","volume":"13","author":"Sharma","year":"2021"},{"key":"10.1016\/j.bbadis.2021.166294_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2020.107762","article-title":"Prediction of potential inhibitors of the dimeric SARS-CoV2 main proteinase through the MM\/GBSA approach","volume":"101","author":"Bello","year":"2020","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.bbadis.2021.166294_bb0035","doi-asserted-by":"crossref","DOI":"10.1007\/s00894-020-04600-4","article-title":"Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM\/GBSA","volume":"26","author":"Bello","year":"2020","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.bbadis.2021.166294_bb0040","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3390\/ph14050454","article-title":"Tenofovir, another inexpensive, well-known and widely available old drug repurposed for SARS-COV-2 infection","volume":"14","author":"Zanella","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bbadis.2021.166294_bb0045","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00819-20","article-title":"Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs","volume":"64","author":"Jeon","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbadis.2021.166294_bb0050","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.pt.2017.02.004","article-title":"Ivermectin \u2013 old drug, new Tricks?","volume":"33","author":"Laing","year":"2017","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijantimicag.2007.08.023","article-title":"Ivermectin: 25 years and still going strong","volume":"31","author":"\u00d5mura","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.bbadis.2021.166294_bb0060","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.6308762","article-title":"Ivermectin: a potent new antiparasitic agent","volume":"221","author":"Campbell","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2021.166294_bb0065","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/nrmicro1048","article-title":"The life and times of ivermectin \u2014 a success story","volume":"2","author":"\u00d5mura","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0070","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijantimicag.2019.05.003","article-title":"Ivermectin: from theory to clinical application","volume":"54","author":"Ashour","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.bbadis.2021.166294_bb0075","doi-asserted-by":"crossref","first-page":"A26","DOI":"10.1111\/j.1365-3156.2004.01211.x","article-title":"Review: the delivery of ivermectin (MectizanR)","volume":"9","author":"Burnham","year":"2004","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.bbadis.2021.166294_bb0080","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3390\/antibiotics10040381","article-title":"Repurposing avermectins and milbemycins against mycobacteroides abscessus and other nontuberculous mycobacteria","volume":"10","author":"Mu\u00f1oz-Mu\u00f1oz","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.bbadis.2021.166294_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105207","article-title":"Ivermectin, a potential anticancer drug derived from an antiparasitic drug","volume":"163","author":"Tang","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbadis.2021.166294_bb0090","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1093\/brain\/awv167","article-title":"DEAD-box RNA helicase DDX23 modulates glioma malignancy via elevating miR-21 biogenesis","volume":"138","author":"Yin","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.bbadis.2021.166294_bb0095","doi-asserted-by":"crossref","DOI":"10.1038\/srep17288","article-title":"Selective targeting of nuclear receptor FXR by avermectin analogues with therapeutic effects on nonalcoholic fatty liver disease","volume":"5","author":"Jin","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2021.166294_bb0100","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/jac\/dks147","article-title":"Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug","volume":"67","author":"Mastrangelo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bbadis.2021.166294_bb0105","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1042\/BJ20120150","article-title":"Ivermectin is a specific inhibitor of importin \u03b1\/\u03b2-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus","volume":"443","author":"Wagstaff","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbadis.2021.166294_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.bbadis.2021.166294_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.663586","article-title":"Repurposing ivermectin for COVID-19: molecular aspects and therapeutic possibilities","volume":"12","author":"Wehbe","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0120","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/00480169.1981.34836","article-title":"An introduction to the avermectins","volume":"29","author":"Campbell","year":"1981","journal-title":"N. Z. Vet. J."},{"key":"10.1016\/j.bbadis.2021.166294_bb0125","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1007\/s43440-020-00195-y","article-title":"Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes","volume":"73","author":"Kaur","year":"2021","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.bbadis.2021.166294_bb0130","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.3390\/cells9092100","article-title":"Ivermectin as a broad-Spectrum host-directed antiviral: the real deal?","volume":"9","author":"Jans","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bbadis.2021.166294_bb0135","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4269\/ajtmh.20-0271","article-title":"Ivermectin and COVID-19: keeping rigor in times of urgency","volume":"102","author":"Chaccour","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.bbadis.2021.166294_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.01196","article-title":"COVID-19 therapeutic options under investigation","volume":"11","author":"Kaddoura","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0145","doi-asserted-by":"crossref","first-page":"9812","DOI":"10.1128\/JVI.01012-07","article-title":"Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum\/golgimembrane","volume":"81","author":"Frieman","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2015.00553","article-title":"Nucleocytoplasmic transport of nucleocapsid proteins of enveloped RNA viruses","volume":"6","author":"Wulan","year":"2015","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0155","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.chom.2016.07.004","article-title":"A screen of FDA-approved drugs for inhibitors of zika virus infection","volume":"20","author":"Barrows","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.bbadis.2021.166294_bb0160","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1602113","article-title":"Zika virus","volume":"374","author":"Petersen","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2021.166294_bb0170","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.virol.2019.10.010","article-title":"Zika virus NS5 nuclear accumulation is protective of protein degradation and is required for viral RNA replication","volume":"541","author":"Ji","year":"2020","journal-title":"Virology"},{"key":"10.1016\/j.bbadis.2021.166294_bb0175","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1128\/CMR.00045-12","article-title":"West Nile virus: biology, transmission, and human infection","volume":"25","author":"Colpitts","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.bbadis.2021.166294_bb0180","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/jac\/dks147","article-title":"Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug","volume":"67","author":"Mastrangelo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bbadis.2021.166294_bb0185","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.cell.2009.01.029","article-title":"The influenza virus enigma","volume":"136","author":"Salomon","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2021.166294_bb0190","article-title":"Influenza a viruses escape from MxA restriction at the expense of efficient nuclear vRNP import","volume":"6","author":"G\u00f6tz","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2021.166294_bb0195","doi-asserted-by":"crossref","first-page":"13053","DOI":"10.1128\/JVI.02220-13","article-title":"The human interferon-induced MxA protein inhibits early stages of influenza a virus infection by retaining the incoming viral genome in the cytoplasm","volume":"87","author":"Xiao","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0200","doi-asserted-by":"crossref","first-page":"8133","DOI":"10.1128\/JVI.00712-11","article-title":"The viral nucleoprotein determines mx sensitivity of influenza a viruses","volume":"85","author":"Zimmermann","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01547","article-title":"Advancements in host-based interventions for influenza treatment","volume":"9","author":"Yip","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0210","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1021\/cb600131q","article-title":"Following the path of the virus: the exploitation of host DNA repair mechanisms by retroviruses","volume":"1","author":"Smith","year":"2006","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104760","article-title":"The broad spectrum antiviral ivermectin targets the host nuclear transport importin \u03b1\/\u03b21 heterodimer","volume":"177","author":"Yang","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.bbadis.2021.166294_bb0220","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2021.166294_bb0225","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jare.2020.03.005","article-title":"COVID-19 infection: emergence, transmission, and characteristics of human coronaviruses","volume":"24","author":"Shereen","year":"2020","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.bbadis.2021.166294_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165878","article-title":"Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach","volume":"1866","author":"Naqvi","year":"2020","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.bbadis.2021.166294_bb0235","first-page":"1","article-title":"Coronaviruses: an overview of their replication and pathogenesis","author":"Fehr","year":"2015","journal-title":"Coronaviruses"},{"key":"10.1016\/j.bbadis.2021.166294_bb0240","doi-asserted-by":"crossref","first-page":"7918","DOI":"10.1128\/JVI.00645-06","article-title":"Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy","volume":"80","author":"Neuman","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0245","first-page":"1","article-title":"Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-\u03b1 with in-vitro effective drug ivermectin","author":"Sen Gupta","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbadis.2021.166294_bb0250","doi-asserted-by":"crossref","first-page":"9812","DOI":"10.1128\/JVI.01012-07","article-title":"Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic Reticulum\/Golgi membrane","volume":"81","author":"Frieman","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113201","article-title":"RNA-dependent RNA polymerase (RdRp) inhibitors: the current landscape and repurposing for the COVID-19 pandemic","volume":"213","author":"Tian","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbadis.2021.166294_bb0260","first-page":"1","article-title":"The binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2","author":"Saha","year":"2021","journal-title":"Struct. Chem."},{"key":"10.1016\/j.bbadis.2021.166294_bb0265","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-020-01577-x","article-title":"Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents","volume":"4","author":"Mody","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0270","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ceb.2019.01.001","article-title":"Inhibitors of nuclear transport","volume":"58","author":"Jans","year":"2019","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0275","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.antiviral.2012.06.008","article-title":"Nuclear trafficking of proteins from RNA viruses: potential target for antivirals?","volume":"95","author":"Caly","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.bbadis.2021.166294_bb0280","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3390\/cells8030281","article-title":"Novel flavivirus antiviral that targets the host nuclear transport importin \u03b1\/\u03b21 heterodimer","volume":"8","author":"Yang","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bbadis.2021.166294_bb0285","unstructured":"Waheed Shouman . Prophylactic Ivermectin in COVID-19 Contacts - Study Results - ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT04422561 (Accessed Jun 10, 2021)."},{"key":"10.1016\/j.bbadis.2021.166294_bb0290","article-title":"Ivermectin and outcomes from Covid-19 pneumonia: a systematic review and meta-analysis of randomized clinical trial studies","author":"Hariyanto","year":"2021","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0295","series-title":"Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: Evidence from in silico studies","author":"Swargiary","year":"2020"},{"key":"10.1016\/j.bbadis.2021.166294_bb0300","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1038\/s41418-020-00633-7","article-title":"An aberrant STAT pathway is central to COVID-19","volume":"27","author":"Matsuyama","year":"2020","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bbadis.2021.166294_bb0305","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.chom.2020.05.008","article-title":"Type I and type III interferons \u2013 induction, signaling, evasion, and application to combat COVID-19","volume":"27","author":"Park","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.bbadis.2021.166294_bb0310","doi-asserted-by":"crossref","first-page":"10262","DOI":"10.1074\/jbc.M116.745729","article-title":"Enterovirus 71 suppresses interferon responses by blocking Janus kinase (JAK)\/signal transducer and activator of transcription (STAT) signaling through inducing karyopherin-\u03b11 degradation","volume":"292","author":"Wang","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2021.166294_bb0315","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.3390\/ijms20194870","article-title":"STAT3 regulates the type I IFN-mediated antiviral response by interfering with the nuclear entry of STAT1","volume":"20","author":"Wang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbadis.2021.166294_bb0320","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1165\/rcmb.2012-0100TR","article-title":"Human epidermal growth factor receptor signaling in acute lung injury","volume":"47","author":"Finigan","year":"2012","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0325","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.bbrc.2016.06.065","article-title":"Plasminogen activator inhibitor-1 stimulates macrophage activation through toll-like Receptor-4","volume":"477","author":"Gupta","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbadis.2021.166294_bb0330","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1165\/rcmb.2008-0003ED","article-title":"What the lung has taught us about latent TGF-\u03b2 activation","volume":"39","author":"Aluwihare","year":"2008","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0335","doi-asserted-by":"crossref","first-page":"855","DOI":"10.4049\/jimmunol.1402513","article-title":"The acute respiratory distress syndrome: from mechanism to translation","volume":"194","author":"Han","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0340","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1158\/0008-5472.CAN-15-2887","article-title":"Ivermectin induces cytostatic autophagy by blocking the PAK1\/Akt Axis in breast cancer","volume":"76","author":"Dou","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbadis.2021.166294_bb0345","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.3390\/ijms22041737","article-title":"Understanding viral infection mechanisms and patient symptoms for the development of COVID-19 therapeutics","volume":"22","author":"Choi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbadis.2021.166294_bb0350","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41423-020-0458-z","article-title":"Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies","volume":"17","author":"Yi","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.145325","article-title":"The potential involvement of JAK-STAT signalling pathway in the COVID-19 infection assisted by ACE2","volume":"768","author":"Luo","year":"2021","journal-title":"Gene"},{"key":"10.1016\/j.bbadis.2021.166294_bb0360","series-title":"Activation of the SARS-CoV-2 receptorAce2by cytokines through pan JAK-STAT enhancers","author":"Hennighausen","year":"2020"},{"key":"10.1016\/j.bbadis.2021.166294_bb0365","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/fvl-2020-0342","article-title":"Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in-silico approach","volume":"16","author":"Choudhury","year":"2021","journal-title":"Futur. Virol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0370","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.21873\/invivo.12134","article-title":"Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2","volume":"34","author":"Lehrer","year":"2020","journal-title":"In Vivo"},{"key":"10.1016\/j.bbadis.2021.166294_bb0375","first-page":"1","article-title":"Elucidation of the inhibitory activity of ivermectin with host nuclear importin \u03b1 and several SARS-CoV-2 targets","author":"Bello","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbadis.2021.166294_bb0380","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-88630-9","article-title":"The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors","volume":"11","author":"Silvestrini","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2021.166294_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2020.107762","article-title":"Prediction of potential inhibitors of the dimeric SARS-CoV2 main proteinase through the MM\/GBSA approach","volume":"101","author":"Bello","year":"2020","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.bbadis.2021.166294_bb0390","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2021.166294_bb0395","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2021.166294_bb0400","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1107\/S2053230X20011814","article-title":"Room-temperature neutron and X-ray data collection of 3CL mprofrom SARS-CoV-2","volume":"76","author":"Kneller","year":"2020","journal-title":"Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun."},{"key":"10.1016\/j.bbadis.2021.166294_bb0405","article-title":"Design of wide-spectrum inhibitors targeting coronavirus main proteases","volume":"3","author":"Yang","year":"2005","journal-title":"PLoS Biol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0410","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2021.166294_bb0415","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jtbi.2008.07.030","article-title":"Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors","volume":"254","author":"Nukoolkarn","year":"2008","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.bbadis.2021.166294_bb0425","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2021.166294_bb0430","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.616341","article-title":"Recent Progress in the drug development targeting SARS-CoV-2 Main protease as treatment for COVID-19","volume":"7","author":"Cui","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bbadis.2021.166294_bb0435","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2021.166294_bb0440","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jtbi.2008.07.030","article-title":"Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors","volume":"254","author":"Nukoolkarn","year":"2008","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.bbadis.2021.166294_bb0445","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/1061186X.2020.1853736","article-title":"Potential inhibitors of SARS-CoV-2: recent advances","volume":"29","author":"Jamalipour Soufi","year":"2020","journal-title":"J. Drug Target."},{"key":"10.1016\/j.bbadis.2021.166294_bb0450","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3390\/v13060989","article-title":"Effects of a single dose of ivermectin on viral and clinical outcomes in asymptomatic SARS-CoV-2 infected subjects: a pilot clinical trial in Lebanon","volume":"13","author":"Samaha","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.bbadis.2021.166294_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30883-5","article-title":"Ct values and infectivity of SARS-CoV-2 on surfaces","volume":"21","author":"Kampf","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.bbadis.2021.166294_bb0460","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1097\/MJT.0000000000001377","article-title":"Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19","volume":"28","author":"Kory","year":"2021","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.bbadis.2021.166294_bb0465","series-title":"Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic","author":"Elgazzar","year":"2020"},{"key":"10.1016\/j.bbadis.2021.166294_bb0470","doi-asserted-by":"crossref","DOI":"10.31546\/2633-8653.1007","article-title":"Study of the efficacy and safety of topical ivermectin + iota-carrageenan in the prophylaxis against COVID-19 in health personnel","volume":"2","author":"H\u00e9ctor","year":"2020","journal-title":"J. Biomed. Res. Clin. Investig."},{"key":"10.1016\/j.bbadis.2021.166294_bb0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242184","article-title":"Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients","volume":"15","author":"Camprub\u00ed","year":"2020","journal-title":"PLOS ONE"},{"key":"10.1016\/j.bbadis.2021.166294_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100959","article-title":"Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial","volume":"37","author":"Krolewiecki","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.bbadis.2021.166294_bb0485","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1001\/jama.2021.3071","article-title":"Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19","volume":"325","author":"L\u00f3pez-Medina","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.bbadis.2021.166294_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100744","article-title":"Is ivermectin ready to be part of a public health policy for COVID-19 prophylaxis?","volume":"32","author":"Ram\u00edrez","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.bbadis.2021.166294_bb0495","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/cpt.1889","article-title":"The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19","volume":"108","author":"Schmith","year":"2020","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443921002271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443921002271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T05:04:38Z","timestamp":1760418278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443921002271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":97,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0925443921002271"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2021.166294","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2021.166294","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"166294"}}